Clinical trials: Haemodialysis
Renal Impairment, Healthy Volunteer
A Study to Assess the Safety of Experimental Medication BMS986165 in Participants With Normal Kidney Function and Participants With Mild to End-Stage Kidney Disease.
The purpose of this study is to investigate BMS-986165 in participants with different levels of kidney function.
- Trial name
- NCT03890770
- Testing
- BMS-986165
- Where
- 6 sites in United States, Czechia and 2 more
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Catheter-Related Infections, Citrate Adverse Reaction
DuraLock-C Catheter Lock Solution
To evaluate the safety and performance of DuraLock-C 4.0%, 30.0%, and 46.7% for the maintenance of central venous catheter (CVC) patency in adult hemodialysis (HD) patients
- Trial name
- NCT04787926
- Testing
- Locking Solution
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Medical Components, Inc dba MedComp
Renal Dialysis, Kidney Failure, Chronic
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-2060 after intravenous (IV) administration of single and multiple doses in older adult participants with…
- Trial name
- NCT03873038
- Testing
- MK-2060
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Merck Sharp & Dohme LLC
End Stage Renal Disease, Inflammation
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
The study is a prospective cohort trial utilizing sequential laboratory results from excess serum obtained from hemodialysis patients (acting as their own controls).
- Trial name
- NCT00440908
- Where
- 2 sites in United States
- Volunteers
- 2,500 people
- Sponsor
- Fresenius Medical Care North America
Patients on Hemodialysis
An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis
A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis
- Trial name
- NCT06849778
- Testing
- TS-172
- Where
- Japan
- Volunteers
- 7 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Renal Anemia
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
This study is aimed to comprehensively establish the bio-similarity/bioequivalence in EPIAO® and EPREX® in terms of 52-week comparisons in efficacy, safety and immunogenicity.
- Trial name
- BEAT_002 (NCT02947438)
- Testing
- EPREX®, EPIAO®
- Where
- 19 sites in Russia, Thailand
- Volunteers
- 207 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Anemia
A Study of Monthly Intravenous C.E.R.A. (Mircera) in Hemodialysis Participants With Chronic Renal Anemia
This single arm study will assess the efficacy, safety and tolerability of once-monthly administration of intravenous methoxy polyethylene glycolepoetin beta (Mircera) for the maintenance of hemoglobin levels in hemodialysis…
- Trial name
- CARISMA (NCT00699348)
- Testing
- Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
- Where
- 60 sites in Italy
- Volunteers
- 351 people
- Sponsor
- Hoffmann-La Roche
Chronic Kidney Disease, Secondary Hyperparathyroidism
Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D
Evaluates the effectiveness of on-label Paricalcitol versus Cinacalcet with Low-Dose Vitamin D.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Hemodialysis
- Trial name
- IMPACT SHPT (NCT00977080)
- Testing
- Paricalcitol, Cinacalcet
- Where
- 83 sites in United States, Czechia and 10 more
- Volunteers
- 272 people
- Sponsor
- Abbott
Anemia of Chronic Kidney Disease
Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease
Study to evaluate the effect of lapatinib, a breast cancer resistance protein (BCRP) inhibitor, on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety and tolerability of JTZ-951 when administered alone and one hour…
- Trial name
- NCT02581124
- Testing
- JTZ-951, Lapatinib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Shionogi Inc.
Anemia of Chronic Kidney Disease
Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients
Anticalins® are engineered human proteins that are able to bind specific target molecules. The Anticalin PRS-080#022-DP to be investigated in this study is directed against hepcidin and is intended for the treatment of anemia of…
- Trial name
- NCT02754167
- Testing
- PRS-080#022-DP
- Where
- 2 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Pieris Pharmaceuticals GmbH
Hemodialysis, Clinical Assessment
Contactless Optical Monitoring of AV Access Using the PatenSee System in Outpatient Hemodialysis Patients
This is a prospective, non-interventional, single arm, international multicenter study in which up to 120 adult participants with kidney failure requiring regular hemodialysis through arteriovenous (AV) access (AV fistula or…
- Trial name
- NCT07194395
- Testing
- PatenSee System
- Where
- 2 sites in United States, Israel
- Volunteers
- 90 people
- Sponsor
- PatenSee Ltd.
Secondary Hyperparathyroidism, Chronic Kidney Disease
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by > 30% from baseline among patients with…
- Trial name
- NCT01896232
- Testing
- Etelcalcetide, Cinacalcet
- Where
- 182 sites in United States, Austria and 20 more
- Volunteers
- 683 people
- Sponsor
- Amgen
Uremic Pruritus
Treatment of Uremic Pruritus With PA101B
This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2, proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring hemodialysis.
- Trial name
- NCT02696499
- Testing
- PA101B
- Where
- 13 sites in United States
- Volunteers
- 70 people
- Sponsor
- Patara Pharma
Hyperphosphatemia
An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)
This phase 3, 8-week, randomized, double-blind, parallel group, multi-center study with a 4-week, placebo-controlled, randomized withdrawal period will evaluate the efficacy, safety and tolerability of Tenapanor to treat…
- Trial name
- NCT02675998
- Testing
- Tenapanor
- Where
- 32 sites in United States
- Volunteers
- 219 people
- Sponsor
- Ardelyx
Chronic Kidney Disease
Novel Endovascular Access Trial (NEAT)
The objective of this study is to evaluate the safety and efficacy of the FLEX System when used to create an arteriovenous fistula (AVF or AV fistula) percutaneously in patients with Chronic Kidney Disease (CKD) who require…
- Trial name
- NEAT (NCT02036671)
- Testing
- The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
- Where
- 9 sites in Australia, Canada and 1 more
- Volunteers
- 80 people
- Sponsor
- C. R. Bard
End Stage Renal Failure on Dialysis
Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis
Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis
- Trial name
- NCT02164175
- Testing
- HeRO Graft implant for dialysis access
- Where
- 3 sites in United States
- Sponsor
- Merit Medical Systems, Inc.
Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
Open-label, pharmacodynamic, safety, pharmacokinetic and efficacy study of Lunacalcipol Injection.
- Conditions
- Stage 5 Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT), Hemodialysis (HD)
- Trial name
- 2007 (NCT01453634)
- Testing
- Lunacalcipol 180, Lunicalcipol 270
- Sponsor
- OPKO Health, Inc.
Chronic Kidney Disease
In Vivo Evaluation of the Nipro Elisio™ Dialyzer
The purpose of this study is to compare the efficacy and biocompatibility of the Nipro Elisio 210H dialyzer between two dialysis modalities, conventional hemodialysis and on line hemodiafiltration.
- Trial name
- NCT01653808
- Testing
- Elisio-210H, conventional hemodialysis, on line hemodiafiltration
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nipro Europe N.V.
End-Stage Renal Disease
Cook Enforcer Post-Market Study
The purpose of this study is to evaluate the performance of the Cook Advance® Enforcer™ 35 Focal-Force PTA Balloon Catheter (or Enforcer balloon) in treating narrowed blood vessels compared to treatment with a conventional…
- Trial name
- NCT03552289
- Testing
- Cook Advance® Enforcer 35 Focal-Force Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter, Conventional angioplasty balloon catheters
- Where
- 5 sites in United States
- Volunteers
- 211 people
- Sponsor
- Cook Research Incorporated
Chronic Kidney Failure, Acute Kidney Failure
Theranova Randomized, Controlled, Trial (RCT) in China
Traditional hemodialysis (HD) therapy is very effective in clearing urea and smaller middle molecules, but is limited in clearing larger middle molecules.
- Trial name
- ROCKet (NCT05309291)
- Testing
- Theranova 400 Dialyzer, FX 800 Dialyzer
- Where
- 10 sites in China
- Volunteers
- 323 people
- Sponsor
- Vantive Health LLC